Indian Express
Sign In | Register Now
Newsletter | ePaper
Indian Express >  National Network > 

HIV/AIDS: 2nd line of treatment too costly, no Govt policy yet

Font Size
Toufiq Rashid Posted: Nov 30, 2006 at 0351 hrs IST
Related Stories: Cardiac arrest cases increase in winters: DoctorsFour genes that drive metabolism pinned downA-Z of the diet you needScientists doubt utility of CT scan as heart testBone of no contentionReconstructive surgery done successfully on teenage girls
NEW DELHI, NOVember 29: Manoj Kumar, 35, has been spending Rs 9,000 per month on his anti-retrovirals (HIV/AIDS drugs) since 2002. Son of a farmer from Varanasi, the treatment has forced his father to sell off land worth Rs 6 lakh.

Kumar’s case is peculiar as the anti-retrovirals provided by the Government don’t work for him and his doctors have put him on a higher level of drugs (second line of treatment), for which he has to pay from his own pocket. These include improved drugs like Tenofavir and Abacavir.

“I have two options — to live and pay huge amounts every month or just prepare to die,’’ said Kumar. “With the high cost of these drugs I don’t know how long can I afford to live anyway,’’ he added.

He is not the only one. At 10 am today, Kumar along with 20 people from across the country, began a protest sit-in at Jantar Mantar to get their voice to the authorities concerned. They will continue their protests till the morning of December 1 — World AIDS Day — when another 300 will join them.

Ads By Google
“Their demand unlike most protesters is for their right to live,’’ said Naresh Yadav, president of the Uttar Pradesh Network of Positive People. These are HIV positive persons who have failed the first line of treatment and are in huge debts paying for the second line of treatment that costs them anything between Rs 9,000 and Rs 15,000 per month. According to the networks, there are about 4,000 patients registered in various hospitals across the country who need similar treatment.

Though the Government has provided medicines for about 96,000 patients as against 47,000 under treatment with the National AIDS Control Organisation (NACO), these are only the basic first line of medication.

Under the Government’s policy the new improved drugs are not available in Government hospitals and patients who have developed resistance to the first line of treatment have to buy them on their own. “Our main effort is to provide the basic treatment for millions of HIV positive people. The second line of treatment is very expensive and we cannot afford to provide it free at this point,’’ said Sujatha Rao, director-general NACO.

Before changing the treatment protocol, NACO is planning a drug resistance study in four centres. The study to be conducted by NARI (PUNE), Tuberculosis Research Centre, Chennai, NICD Kolkata and AIIMS in Delhi is likely to be started early next year.

Ads By Google
Post Comments
Message*
Maximum characters allowed     
 
Name* Email ID*
Subject* Country*
TERMS OF USE:
The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
I agree to the terms of use.
View all Messages [ 0 ]
View all Messages [ 0 ]
Group Websites : Express India | Financial Express | Screen India | Loksatta | Kashmir Live | Biz Publications
Privacy Policy | Feedback | Site MapThe Indian Express Group | Work With Us | Adverise With Us | Contact Us© 2008 Indian Express Newspapers (Mumbai) Ltd. All rights reserved
*Recipient(s) name *
*Recipient(s) e-mail address *
(Separate addresses by commas)
*Your Name *
*Your e-mail address *
Select your Country
Comments(optional)

The name(s) and e-mail address(es) you provide will
not be used for any purpose other than to inform the
recipient(s) of your identity. (*mandatory field)
 
Close